Experimental treatments for mitochondrial dysfunction in sepsis: A narrative review

Journal of Research in Medical Sciences

Volumn 20, Issue 2, 2015, Pages 185-195

  Zheng, Guilang ^a   Lyu, Juanjuan ^a   Huang, Jingda ^a   Xiang, Dan ^a   Xie, Meiyan ^a   Zeng, Qiyi ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Drug; Mitochondria; Mitochondrial dysfunction; Sepsis

Indexed keywords

ACETYL COENZYME A; ACETYLCYSTEINE; CAFFEINE; CARNITINE; CYCLIC AMP; CYCLOSPORIN A; CYTOCHROME C; CYTOCHROME C OXIDASE; GLUTAMIC ACID; GLUTATHIONE; HEME OXYGENASE; INSULIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MELATONIN; MESSENGER RNA; NICOTINAMIDE NUCLEOTIDE ADENYLYLTRANSFERASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXOGLUTARATE DEHYDROGENASE; PROSTAGLANDIN SYNTHASE; PYRUVATE DEHYDROGENASE; REACTIVE OXYGEN METABOLITE; TEMPOL; THIOCTIC ACID; TRICARBOXYLIC ACID; TUMOR NECROSIS FACTOR; UBIQUINONE; UNINDEXED DRUG;

APOPTOSIS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ELECTRON TRANSPORT; HORMONAL THERAPY; HUMAN; MEMBRANE STABILIZATION; MITOCHONDRIAL PERMEABILITY; MULTIPLE ORGAN FAILURE; OXIDATIVE PHOSPHORYLATION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; RESPIRATORY CHAIN; RESPIRATORY DISTRESS SYNDROME; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

EID: 84926309518     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Spronk PE, Kanoore-Edul VS, Ince C. Microcirculatory and Mitochondrial Distress Syndrome (MMDS): A new look at sepsi. In: Pinsky M, Payen D, editors. Functional Hemodynamic Monitoring. Berlin, Heidelberg: Springer; 2005. p. 47-67.
3. Dare AJ, Phillips AR, Hickey AJ, Mittal A, Loveday B, Thompson N, et al. A systematic review of experimental treatments for mitochondrial dysfunction in sepsis and multiple organ dysfunction syndrome. Free Radic Biol Med 2009;47:1517-25.
4. Protti A, Carré J, Frost MT, Taylor V, Stidwill R, Rudiger A, et al. Succinate recovers mitochondrial oxygen consumption in septic rat skeletal muscle. Crit Care Med 2007;35:2150-5.
5. Spath B, Hansen A, Bokemeyer C, Langer F. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists. Platelets 2012;23:60-8.
6. Wernerman J. Clinical use of glutamine supplementation. J Nutr 2008;138:2040S-4.
7. Briassouli E, Briassoulis G. Glutamine randomized studies in early life: The unsolved riddle of experimental and clinical studies. Clin Dev Immunol 2012;2012:749189.
8. Groening P, Huang Z, La Gamma EF, Levy RJ. Glutamine restores myocardial cytochrome C oxidase activity and improves cardiac function during experimental sepsis. JPEN J Parenter Enteral Nutr 2011;35:249-54.
9. Garrett-Cox RG, Stefanutti G, Booth C, Klein NJ, Pierro A, Eaton S. Glutamine decreases inflammation in infant rat endotoxemia. J Pediatr Surg 2009;44:523-9.
10. Lu J, Wang XY, Tang WH. Glutamine attenuates nitric oxide synthase expression and mitochondria membrane potential decrease in interleukin-1beta-activated rat hepatocytes. Eur J Nutr 2009;48:333-9.
11. Nalos M, Asfar P, Ichai C, Radermacher P, Leverve XM, Fröba G. Adenosine triphosphate-magnesium chloride: Relevance for intensive care. Intensive Care Med 2003;29:10-8.
12. Huang LJ, Hsu C, Tsai TN, Wang SJ, Yang RC. Suppression of mitochondrial ATPase inhibitor protein (IF1) in the liver of late septic rats. Biochim Biophys Acta 2007;1767:888-96.
13. Flanagan JL, Simmons PA, Vehige J, Willcox MD, Garrett Q. Role of carnitine in disease. Nutr Metab (Lond) 2010;7:30.
14. Pignatelli P, Tellan G, Marandola M, Carnevale R, Loffredo L, Schillizzi M, et al. Effect of L-carnitine on oxidative stress and platelet activation after major surgery. Acta Anaesthesiol Scand 2011;55:1022-8.
15. Lewis RJ, Viele K, Broglio K, Berry SM, Jones AE. An adaptive, phase II, dose-finding clinical trial design to evaluate L-carnitine in the treatment of septic shock based on efficacy and predictive probability of subsequent phase III success. Crit Care Med 2013;41:1674-8.
16. Abd El-Gawad HM, Khalifa AE. Quercetin, coenzyme Q10, and L-canavanine as protective agents against lipid peroxidation and nitric oxide generation in endotoxin-induced shock in rat brain. Pharmacol Res 2001;43:257-63.
17. Dupic L, Huet O, Duranteau J. Coenzyme Q10 deficiency in septic shock patients. Crit Care 2011;15:194.
18. Hüttemann M, Pecina P, Rainbolt M, Sanderson TH, Kagan VE, Samavati L, et al. The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: From respiration to apoptosis. Mitochondrion 2011;11:369-81.
19. Piel DA, Gruber PJ, Weinheimer CJ, Courtois MR, Robertson CM, Coopersmith CM, et al. Mitochondrial resuscitation with exogenous cytochrome c in the septic heart. Crit Care Med 2007;35:2120-7.
20. Fink MP. Administration of exogenous cytochrome c as a novel approach for the treatment of cytopathic hypoxia. Crit Care Med 2007;35:2224-5.
21. Goldfarb RD. Caffeine-stimulated mechanisms for improved cardiac function during sepsis. Crit Care Med 2009;37:1517-8.
22. Verma R, Huang Z, Deutschman CS, Levy RJ. Caffeine restores myocardial cytochrome oxidase activity and improves cardiac function during sepsis. Crit Care Med 2009;37:1397-402.
23. Vanasco V, Cimolai MC, Evelson P, Alvarez S. The oxidative stress and the mitochondrial dysfunction caused by endotoxemia are prevented by alpha-lipoic acid. Free Radic Res 2008;42:815-23.
24. Jiang S, Zhu W, Li C, Zhang X, Lu T, Ding Z, et al. α-Lipoic acid attenuates LPS-induced cardiac dysfunction through a PI3K/Akt-dependent mechanism. Int Immunopharmacol 2013;16:100-7.
25. Thomas RR, Khan SM, Portell FR, Smigrodzki RM, Bennett JP Jr. Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin. Mitochondrion 2011;11:108-18.
26. Aslami H, Pulskens WP, Kuipers MT, Bos AP, van Kuilenburg AB, Wanders RJ, et al. Hydrogen sulfide donor NaHS reduces organ injury in a rat model of pneumococcal pneumosepsis, associated with improved bio-energetic status. PLoS One 2013;8:e63497.
27. Lowes DA, Thottakam BM, Webster NR, Murphy MP, Galley HF. The mitochondria-targeted antioxidant MitoQ protects against organ damage in a lipopolysaccharide-peptidoglycan model of sepsis. Free Radic Biol Med 2008;45:1559-65.
28. Supinski GS, Murphy MP, Callahan LA. MitoQ administration prevents endotoxin-induced cardiac dysfunction. Am J Physiol Regul Integr Comp Physiol 2009;297:R1095-102.
29. Nin N, Cassina A, Boggia J, Alfonso E, Botti H, Peluffo G, et al. Septic diaphragmatic dysfunction is prevented by Mn (III) porphyrin therapy and inducible nitric oxide synthase inhibition. Intensive Care Med 2004;30:2271-8.
30. Hollins DL, Suliman HB, Piantadosi CA, Carraway MS. Glutathione regulates susceptibility to oxidant-induced mitochondrial DNA damage in human lymphocytes. Free Radic Biol Med 2006;40:1220-6.
31. Sheu SS, Nauduri D, Anders MW. Targeting antioxidants to mitochondria: A new therapeutic direction. Biochim Biophys Acta 2006;1762:256-65.
32. Liao XY, Lin JD, Ni XX, Lin H. Effects of reduced glutathione on plasma level of cytokines and pulmonary ultrastructure in rats with sepsis. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2010;22:282-4.
33. Visvanathan V. N-acetylcysteine for sepsis and systemic inflammatory response in adults. Crit Care Nurse 2013;33:76-7.
34. Zapelini PH, Rezin GT, Cardoso MR, Ritter C, Klamt F, Moreira JC, et al. Antioxidant treatment reverses mitochondrial dysfunction in a sepsis animal model. Mitochondrion 2008;8:211-8.
35. Belcher E, Mitchell J, Evans T. Myocardial dysfunction in sepsis: No role for NO? Heart 2002;87:507-9.
36. Hsiao CC, Lee CH, Tsao LY, Lo HC. The dose-dependent immunoregulatory effects of the nitric oxide synthase inhibitor N(G)-nitro-L-arginine methyl ester in rats with sub-acute peritonitis. PLoS One 2012;7:e42467.
37. Callahan LA, Stofan DA, Szweda LI, Nethery DE, Supinski GS. Free radicals alter maximal diaphragmatic mitochondrial oxygen consumption in endotoxin-induced sepsis. Free Radic Biol Med 2001;30:129-38.
38. Ninković MB, Malicević ZM, Jelenković A, Dukić MM, Jovanović MD, Stevanović ID. Nitric oxide synthase inhibitors partially inhibit oxidative stress development in the rat brain during sepsis provoked by cecal ligation and puncture. Gen Physiol Biophys 2009;28 Spec No:243-50.
39. Cobb JP. Nitric oxide synthase inhibition as therapy for sepsis: A decade of promise. Surg Infect (Larchmt) 2001;2:93-100.
40. Aytekin FO, Teke Z, Aydin C, Kabay B, Yenisey C, Sacar S, et al. Effects of a membrane-permeable radical scavenger, Tempol, on healing of colonic anastomoses in the cecal ligation and puncture model of polymicrobial sepsis in rats. Am J Surg 2007;193:723-9.
41. Liaw WJ, Chen TH, Lai ZZ, Chen SJ, Chen A, Tzao C, et al. Effects of a membrane-permeable radical scavenger, Tempol, on intraperitoneal sepsis-induced organ injury in rats. Shock 2005;23:88-96.
42. Matejovic M, Krouzecky A, Martinkova V, Rokyta R Jr, Radej J, Kralova H, et al. Effects of tempol, a free radical scavenger, on long-term hyperdynamic porcine bacteremia. Crit Care Med 2005;33:1057-63.
43. Yuksel BC, Serdar SE, Tuncel A, Uzum N, Ataoglu O, Atan A, et al. Effect of tempol, a membrane-permeable radical scavenger, on mesenteric blood flow and organ injury in a murine cecal ligation and puncture model of septic shock. Eur Surg Res 2009;43:219-27.
44. Cuzzocrea S, McDonald MC, Mazzon E, Filipe HM, Centorrino T, Lepore V, et al. Beneficial effects of tempol, a membrane-permeable radical scavenger, on the multiple organ failure induced by zymosan in the rat. Crit Care Med 2001;29:102-11.
45. Fink MP, Macias CA, Xiao J, Tyurina YY, Delude RL, Greenberger JS, et al. Hemigramicidin-TEMPO conjugates: Novel mitochondria-targeted antioxidants. Crit Care Med 2007;35:S461-7.
46. Macias CA, Chiao JW, Xiao J, Arora DS, Tyurina YY, Delude RL, et al. Treatment with a novel hemigramicidin-TEMPO conjugate prolongs survival in a rat model of lethal hemorrhagic shock. Ann Surg 2007;245:305-14.
47. Miyaji T, Hu X, Yuen PS, Muramatsu Y, Iyer S, Hewitt SM, et al. Ethyl pyruvate decreases sepsis-induced acute renal failure and multiple organ damage in aged mice. Kidney Int 2003;64:1620-31.
48. Ulloa L, Ochani M, Yang H, Tanovic M, Halperin D, Yang R, et al. Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. Proc Natl Acad Sci USA 2002;99:12351-6.
49. Fink MP. Ringer’s ethyl pyruvate solution: A novel resuscitation fluid for the treatment of hemorrhagic shock and sepsis. J Trauma 2003;54:S141-3.
50. Hauser B, Kick J, Asfar P, Ehrmann U, Albicini M, Vogt J, et al. Ethyl pyruvate improves systemic and hepatosplanchnic hemodynamics and prevents lipid peroxidation in a porcine model of resuscitated hyperdynamic endotoxemia. Crit Care Med 2005;33:2034-42.
51. Bennett-Guerrero E, Swaminathan M, Grigore AM, Roach GW, Aberle LG, Johnston JM, et al. A phase II multicenter double-blind placebo-controlled study of ethyl pyruvate in high-risk patients undergoing cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2009;23:324-9.
52. Supinski GS, Callahan LA. Hemin prevents cardiac and diaphragm mitochondrial dysfunction in sepsis. Free Radic Biol Med 2006;40:127-37.
53. Bortscher S, Chang J, Vilz TO, Schäfer N, Sommer N, Wehner S, et al. Hemin induction of HO-1 protects against LPS-induced septic ileus. J Surg Res 2012;178:866-73.
54. Rayamajhi N, Kim SK, Go H, Joe Y, Callaway Z, Kang JG, et al. Quercetin induces mitochondrial biogenesis through activation of HO-1 in HepG2 cells. Oxid Med Cell Longev 2013;2013:154279.
55. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D, et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reperfusion injury. J Mol Cell Cardiol 2005;38:367-74.
56. Fauvel H, Marchetti P, Obert G, Joulain O, Chopin C, Formstecher P, et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. Am J Respir Crit Care Med 2002;165:449-55.
57. Crouser ED, Julian MW, Joshi MS, Bauer JA, Wewers MD, Hart JM, et al. Cyclosporin A ameliorates mitochondrial ultrastructural injury in the ileum during acute endotoxemia. Crit Care Med 2002;30:2722-8.
58. Joshi MS, Bauer JA, Julian MW, Crouser ED. Cyclosporin A attenuates left ventricular dysfunction in a feline model of acute sepsis: Relation to TLR4 induction, NOS2 induction and protein nitration. FASEB J 2004;18:A592.
59. Joshi MS, Bauer JA, Julian MW, Crouser ED. Prevention of sepsis related cardiac dysfunction and mitochondrial injury by Cyclosporin A in a feline model of acute sepsis. FASEB J 2004;18:A591-2.
60. Gomez L, Li B, Mewton N, Sanchez I, Piot C, Elbaz M, et al. Inhibition of mitochondrial permeability transition pore opening: Translation to patients. Cardiovasc Res 2009 15;83:226-33.
61. Larche J, Lancel S, Hassoun SM, Favory R, Decoster B, Marchetti P, et al. Inhibition of mitochondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. J Am Coll Cardiol 2006;48:377-85.
62. León J, Acuña-Castroviejo D, Escames G, Tan DX, Reiter RJ. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005;38:1-9.
63. Calamita G, Ferri D, Gena P, Liquori GE, Cavalier A, Thomas D, et al. The inner mitochondrial membrane has aquaporin-8 water channels and is highly permeable to water. J Biol Chem 2005 29;280:17149-53.
64. Wang JQ, Zhang L, Tao XG, Wei L, Liu B, Huang LL, et al. Tetramethylpyrazine upregulates the aquaporin 8 expression of hepatocellular mitochondria in septic rats. J Surg Res 2013;185:286-93.
65. Hirsch IB, Coviello A. Intensive insulin therapy in critically ill patients. N Engl J Med 2002;346:1586-8.
66. Zeng QY, Zhang CM, Qian XH. Protective effects of continue insulin infusion on liver mitochondrion in the early stage of septic rats. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi 2009;25:525-8.
67. Vanhorebeek I, De Vos R, Mesotten D, Wouters PJ, De Wolf-Peeters C, Van den Berghe G. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet 2005;365:53-9.
68. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci 2004;75:765-90.
69. Ortiz F, García JA, Acuña-Castroviejo D, Doerrier C, López A, Venegas C, et al. The beneficial effects of melatonin against heart mitochondrial impairment during sepsis: Inhibition of iNOS and preservation of nNOS. J Pineal Res 2014;56:71-81.
70. Escames G, López LC, Tapias V, Utrilla P, Reiter RJ, Hitos AB, et al. Melatonin counteracts inducible mitochondrial nitric oxide synthase-dependent mitochondrial dysfunction in skeletal muscle of septic mice. J Pineal Res 2006;40:71-8.
71. Escames G, López LC, Ortiz F, López A, García JA, Ros E, et al. Attenuation of cardiac mitochondrial dysfunction by melatonin in septic mice. FEBS J 2007;274:2135-47.
72. Yerer MB, Yapislar H, Aydogan S, Yalcin O, Baskurt O. Lipid peroxidation and deformability of red blood cells in experimental sepsis in rats: The protective effects of melatonin. Clin Hemorheol Microcirc 2004;30:77-82.
73. Donnino MW, Cocchi MN, Salciccioli JD, Kim D, Naini AB, Buettner C, et al. Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock. Crit Care 2011 9;15:R189.
74. Rocha M, Herance R, Rovira S, Hernández-Mijares A, Victor VM. Mitochondrial dysfunction and antioxidant therapy in sepsis. Infect Disord Drug Targets 2012;12:161-78.
75. Li LF, Kao KC, Yang CT, Huang CC, Liu YY. Ethyl pyruvate reduces ventilation-induced neutrophil infiltration and oxidative stress. Exp Biol Med (Maywood) 2012;237:720-7.
76. Venkataraman R, Kellum JA, Song M, Fink MP. Resuscitation with Ringer’s ethyl pyruvate solution prolongs survival and modulates plasma cytokine and nitrite/nitrate concentrations in a rat model of lipopolysaccharide-induced shock. Shock 2002;18:507-12.
77. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
78. Choi HM, Jo SK, Kim SH, Lee JW, Cho E, Hyun YY, et al. Glucocorticoids attenuate septic acute kidney injury. Biochem Biophys Res Commun 2013;435:678-84.
79. Escames G, León J, Macías M, Khaldy H, Acuña-Castroviejo D. Melatonin counteracts lipopolysaccharide-induced expression and activity of mitochondrial nitric oxide synthase in rats. FASEB J 2003;17:932-4.
80. Paskaloğlu K, Sener G, Kapucu C, Ayanoğlu-Dülger G. Melatonin treatment protects against sepsis-induced functional and biochemical changes in rat ileum and urinary bladder. Life Sci 2004;74:1093-104.
81. Kurdi MS, Patel T. The role of melatonin in anaesthesia and critical care. Indian J Anaesth 2013;57:137-44.
82. Kaur C, Ling EA. Antioxidants and neuroprotection in the adult and developing central nervous system. Curr Med Chem 2008;15:3068-80.
83. Srinivasan V, Mohamed M, Kato H. Melatonin in bacterial and viral infections with focus on sepsis: A review. Recent Pat Endocr Metab Immune Drug Discov 2012;6:30-9.
84. Srinivasan V, Pandi-Perumal SR, Spence DW, Kato H, Cardinali DP. Melatonin in septic shock: Some recent concepts. J Crit Care 2010;25:656.e1-6.
85. Gitto E, Karbownik M, Reiter RJ, Tan DX, Cuzzocrea S, Chiurazzi P, et al. Effects of melatonin treatment in septic newborns. Pediatr Res 2001;50:756-60.
86. Bagci S, Horoz ÖÖ, Yildizdas D, Reinsberg J, Bartmann P, Müller A. Melatonin status in pediatric intensive care patients with sepsis. Pediatr Crit Care Med 2012;13:e120-3.